VEGF-B

VEGF-B Informations sur la molécule

Nom anglais	Vascular endothelial growth factor B	Nombre de médicaments commercialisés	1
Nombre de médicaments cliniques	4	Alias de la cible	VEGF-related factor，VRF，VEGFB，VEGF-B，VEGFL，Vascular Endothelial Growth Factor B
Phase de R&D la plus avancée	Approved

Nom anglais	Vascular endothelial growth factor B
Alias de la cible	VEGF-related factor，VRF，VEGFB，VEGF-B，VEGFL，Vascular Endothelial Growth Factor B
Nombre de médicaments commercialisés	1
Nombre de médicaments cliniques	4
Phase de R&D la plus avancée	Approved

VEGF-B Liste de produits

Attribut
Protein (1)
Bibliothèque de produits
En ligne (1)
Espèces
Human (1)
Étiquette
His Tag (1)
Marqueur
Unconjugated (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
VE6-H5225	Human	HEK293	Human VEGF-B Protein, His Tag				Ajouter au panier

Quantité totale1

VEGF-BContexte de la molécule

Vascular endothelial growth factor B (VEGFB) is also known as VEGF-related factor (VRF), is a secreted O-glycosylated protein, which belongs to the PDGF/VEGF growth factor family. VEGFB is expressed in all tissues except liver. Highest levels found in heart, skeletal muscle and pancreas. VEGFB is growth factor for endothelial cells. VEGF-B seems to play a role only in the maintenance of newly formed blood vessels during pathological conditions. VEGF-B also plays an important role on several types of neurons. It is important for the protection of neurons in the retina and the cerebral cortex during stroke and of motoneurons during motor neuron diseases such as amyotrophic lateral sclerosis.VEGF-B167 binds heparin and neuropilin-1 whereas the binding to neuropilin-1 of VEGF-B186 is regulated by proteolysis.

VEGF-BAlias de la molécule

VRF,VEGFL,VEGFB,VEGF-B

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
4D-150	4D-150	Phase 3 Clinical	4d Molecular Therapeutics Inc	Diabetic macular oedema; Diabetic Retinopathy; Macular Degeneration; Wet Macular Degeneration	Details
Reflocibart	2H-10; CSL-346	Phase 2 Clinical	Csl Ltd	Diabetic Nephropathies	Details
PB-101	PB-101	Phase 1 Clinical	Panolos Bioscience Inc	Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Colorectal Neoplasms; Neoplasms; Solid tumours; Stomach Neoplasms	Details
EB-105	EB-105	Phase 1 Clinical	Eluminex Biosciences (Suzhou) Ltd	Diabetic macular oedema; Diabetic Retinopathy	Details

Informations sur les médicaments commercialisés

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Plus ancien nom de marque	Pays d'approbation le plus ancien	Indication la plus ancienne	Société d'approbation la plus ancienne	Date d'approbation la plus ancienne	Indication	Essai clinique
Ziv-aflibercept	AVE-0005; BAY-865321	Approved	Regeneron Pharmaceuticals Inc, Sanofi	Zaltrap	United States	Colorectal Neoplasms	Sanofi-Aventis U.S. Llc	2012-08-03	Adenocarcinoma, Follicular; Ascites; Astrocytoma; Brain Neoplasms; Breast Neoplasms; Carcinoma; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Carcinoma, Ovarian Epithelial; Carcinoma, Papillary; Carcinoma, Renal Cell; Carcinoma, Squamous Cell; Carcinoma, Transitional Cell; Colonic Neoplasms; Colorectal Neoplasms; Endometrial Neoplasms; Fallopian Tube Neoplasms; Genital Neoplasms, Female; Glioblastoma; Glioma; Gliosarcoma; Leiomyosarcoma; Leukemia; Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative; Leukemia, Myelomonocytic, Chronic; Lung Diseases; Lung Neoplasms; Lymphoma; Lymphoma, Non-Hodgkin; Melanoma; Metastatic breast cancer; Multiple Endocrine Neoplasia Type 1; Multiple Myeloma; Myelodysplastic Syndromes; Myelodysplastic-Myeloproliferative Diseases; Neoplasm Metastasis; Neoplasms; Oligodendroglioma; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Neoplasms; Prostatic Neoplasms; Rectal Neoplasms; Retinal Vein Occlusion; Skin Melanoma; Small Cell Lung Carcinoma; Solid tumours; Thyroid	Details